There has been a lot of web searching for information about Tysabri (natalizumab) [formerly Antegren] in the wake of the FDA approval last month for use in multiple sclerosis. A lot of searching has been by patients and concerned family members, clinicians and students, and those interested in the business applications.
I posted a couple of entries about the drug approval that are found in the November archives. I've been looking for a business commentary to note and found one earlier today:
In the business-world end of this, here is an interesting commentary from the 24th of November by a writer for TheStreet.com:
What Price Tysabri?
By Adam Feuerstein
Senior Writer, TheStreet.com
11/24/2004 8:00 AM EST
Read the opinion article